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Background: Germline alterations in the proapoptotic protein 
 Bcl-2–like 11 (BIM) can have a crucial role in tumor response to 
treatment. To determine the clinical utility of detecting BIM deletion 
polymorphism in non–small-cell lung cancer positive for epidermal 
growth factor receptor (EGFR) mutation, we examined outcomes of 
patients with and without BIM alterations.
Methods: We studied 70 patients with EGFR mutation-positive 
non–small-cell lung cancer who were treated with an EGFR tyro-
sine kinase inhibitor between January 2008 and January 2013. BIM 
deletion was analyzed by polymerase chain reaction in 58 samples 
of peripheral blood and 24 formalin-fixed  paraffin-embedded slides 
of surgical specimens (20 of lung tissue and four of brain tissue); 
both blood and tissue specimens were available for 12 patients. We 
retrospectively analyzed clinical characteristics, response rate, tox-
icity, and outcomes among patients with and without BIM deletion.
Results: BIM deletion was present in 13 of 70 patients (18.6%). 
There were no significant differences between patients with and 
without BIM deletion in clinical characteristics, rate of response 
to EGFR tyrosine kinase inhibitor, or incidence of adverse events. 
Patients with BIM deletion had significantly shorter progression-free 
survival (PFS) than those without BIM deletion (median, 227 versus 
533 days; p < 0.001). Multivariate Cox regression analysis showed 
that BIM deletion was an independent indicator of shorter PFS (haz-
ard ratio, 3.99; 95% confidence interval, 1.864–8.547; p < 0.001).
Conclusions: Polymerase chain reaction successfully detected 
BIM deletion in samples of peripheral blood and formalin-fixed 
 paraffin-embedded slides of surgical specimens. BIM deletion was 
the most important independent prognostic factor in shorter PFS.
Key Words: BIM, Non–small-cell lung cancer, Epidermal growth 
factor receptor tyrosine kinase inhibitor.
(J Thorac Oncol. 2014;9: 483–487)
An activating mutation of the epidermal growth factor recep-tor (EGFR) gene is a promising target in the treatment 
of non–small-cell lung cancer (NSCLC).1,2 The frequency of 
EGFR mutations depends on the population studied. In North 
America and Western Europe, approximately 10% of patients 
with NSCLC harbor mutations, whereas in East Asia approxi-
mately 30% have EGFR mutations.3,4 EGFR tyrosine kinase 
inhibitors (EGFR-TKI) such as gefitinib and erlotinib are rec-
ommended for treating EGFR mutation-positive NSCLC.5,6 
NSCLC patients with such mutations who were treated with 
EGFR-TKI as first-line therapy had longer progression-free 
survival (PFS) than did those who received platinum-based 
chemotherapy.7–10 Therefore, detection of EGFR mutations in 
patients with metastatic NSCLC is important in selecting indi-
vidualized therapies.
However, most patients develop a recurrence within 10 to 
16 months after initial EGFR-TKI treatment.11 Approximately 
50% of patients with acquired resistance to EGFR-TKI were 
found to have the EGFR T790M mutation.12,13 Other reported 
mechanisms responsible for acquired resistance are MET 
amplification, in 5% to 10% of cases,14,15 and small-cell can-
cer transformation, in less than 5% of cases.16 However, the 
mechanisms responsible for acquired EGFR-TKI resistance 
are not known in approximately 30% to 40% of patients.11
Bcl-2–like 11 (BIM) is a proapoptotic member of the 
B-cell CLL/Lymphoma 2 (Bcl-2) family of proteins17,18 
and has emerged as a key modulator of apoptosis triggered 
by  EGFR-TKI.19,20 Low expression levels of BIM in pri-
mary tumors are reported to be associated with shorter PFS 
in patients treated with EGFR-TKI.21 Recently, Ng et al.22 
reported a common intronic deletion polymorphism in the gene 
encoding BIM. This polymorphism switched BIM splicing 
from exon 4 to exon 3, which resulted in increased expression 
of BIM isoforms lacking the proapoptotic Bcl-2-homology 
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domain 3 (BH3). After TKI exposure, cells with the BIM 
deletion polymorphism showed decreased induction of 
 exon-4-containing transcripts and, consequently, impaired 
BH3-domain–dependent apoptosis. This germline alteration 
could have a crucial role in determining how a tumor responds 
to treatment. However, few studies have examined the clini-
cal usefulness of detecting BIM deletion polymorphism or the 
clinical characteristics of EGFR mutation-positive NSCLC.
To determine the clinical utility of detecting BIM dele-
tion polymorphism in patients with EGFR mutation-positive 
NSCLC, we examined the outcomes of patients with and 
without BIM alterations.
PATIENTS AND METHODS
Polymerase Chain Reaction
To detect BIM deletion polymorphism, we performed 
two types of polymerase chain reaction (PCR) analysis, 
according to the method of Ng et al.22 In brief, we used a sin-
gle primer set that contains the deletion area in intron 2 and 
two separate primer sets designed for wild-type and deletion 
alleles. The DNA was subjected to PCR amplification using 
primers designed to detect deletion site (2903 bp) in intron 2 
of the BCL2L11 gene. The resulting PCR products from the 
deletion (1285 bp) and wild-type (4188 bp) alleles were ana-
lyzed on agarose gels. In addition, the PCR products for the 
deletion (177 bp) and wild-type (174 bp) alleles were ana-
lyzed on agarose gel. We analyzed 20 cell lines, including the 
 KCL-22 cell (which was reported to have the BIM deletion),22 
and 30 DNA samples from healthy Japanese volunteers.
Clinical Samples
We studied 70 patients with EGFR mutation-positive 
NSCLC who were treated with EGFR-TKI during the period 
from January 2008 to January 2013. BIM deletion polymor-
phism was analyzed by PCR in 58 samples of peripheral 
blood (cell-free DNA in 34, leukocyte DNA in 35) and on 
24 formalin-fixed paraffin-embedded (FFPE) slides of surgi-
cal specimens (20 specimens of lung tissue and four of brain 
tissue); both blood and tissue specimens were available for 12 
patients. To confirm the validity of PCR analysis of two types 
of samples, we compared the results for BIM deletion polymor-
phism identified in lung tissue on FFPE slides with those from 
peripheral blood (cell-free DNA or leukocyte DNA) from the 
same patients (n = 12). DNA was extracted from FFPE slides 
using the QIAamp FFPE Tissue Kit (QIAGEN KK, Tokyo, 
Japan). DNA extraction blood samples were diluted in lysis 
solution to lyse the red cells and the white cell fraction was 
pelleted and washed once in phosphate-buffered saline. DNA 
was extracted from the white cell pellets using the QIAamp 
DNA mini Kit (QIAGEN KK, Tokyo, Japan).
Clinical Outcomes
We retrospectively analyzed the clinical characteristics, 
response rate (RR), disease control rate (DCR), and toxic-
ity of EGFR-TKI in patients with and without BIM deletion 
polymorphism. Toxicity was assessed according to National 
Cancer Institute Common Terminology Criteria for Adverse 
Events, version 3.
We estimated PFS and overall survival (OS) in patients 
with and without BIM deletion polymorphism. The PFS of 
patients treated with EGFR-TKI was assessed from the date 
EGFR-TKI therapy was started to the earliest sign of dis-
ease progression as determined by findings from computed 
tomography or magnetic resonance imaging, according to 
the Response Evaluation Criteria in Solid Tumors. OS was 
defined as the period from the date of diagnosis until death 
from any cause.
Statistical Analysis
Statistical analyses were conducted using SPSS soft-
ware for Windows, version 12.0 (SPSS, Tokyo, Japan). 
Differences in clinical characteristics, RR, DCR, and adverse 
events between patients with and without BIM deletion poly-
morphism were compared using Fisher’s exact test. Survival 
curves were drawn by the Kaplan-Meier method, and statisti-
cal analysis was performed using the log-rank test.
We used univariate analysis and multivariate Cox regres-
sion analysis to identify factors associated with shorter PFS. 
The investigated prognostic factors were age, sex (male versus 
female), performance status (2 versus 1 versus 0), brain metas-
tasis (yes versus no), bone metastasis (yes versus no), pulmo-
nary metastasis (yes versus no), liver metastasis (yes versus 
no), lymph node metastasis (yes versus no), EGFR mutation 
(major mutations [L858R and exon 19 deletion] versus minor 
mutations [other mutations]), EGFR-TKI response (partial 
response versus stable disease), smoking history (pack-years), 
and BIM deletion (yes versus no).
This single-center study was conducted at Toho 
University Omori Medical Center (Tokyo, Japan) and was 
approved by its Human Genome/Gene Analysis Research 
Ethical Committee (Authorization number; 24-1).
RESULTS
Detection of BIM Deletion in Cell 
Lines and Healthy Volunteers
Using the two types of PCR analysis, we analyzed 20 
cell lines and 30 DNA samples from healthy Japanese vol-
unteers. Among the 20 cell lines, only KCL-22 showed BIM 
deletion. As for DNA samples, BIM deletion polymorphism 
was present in six of the 30 (20%) healthy volunteers. There 
was no discordance between the two types of PCR analysis.
TABLE 1.  Presence of BIM Deletion in Patients with EGFR Mutation-Positive NSCLC (n = 70)
Patients with BIM Deletion
Patients without BIM Deletion Frequency of BIM DeletionHeterozygous Deletion Homozygous Deletion
12 1 57 18.6%
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Validation between Blood 
Samples and FFPE Slides
We confirmed the validity between blood samples (leu-
kocyte DNA in 12 and cell-free DNA in four) and FFPE slides 
of surgical specimens (lung tissue in 12): BIM deletion was 
detected in three of 12 patients (25%). There was no discor-
dance between the two sample types.
Detection of BIM Deletion on 
EGFR-Positive NSCLC
We analyzed BIM deletion polymorphism in 70 
patients with EGFR mutation-positive NSCLC who were 
treated with EGFR-TKI. BIM deletion polymorphism was 
present in 13 of the 70 patients (18.6%); homozygous dele-
tion was noted in one and heterozygous deletion in 12. For 
the one case of homozygous deletion, PCR analysis using 
the primer set for the wild-type allele showed no amplifica-
tion (Table 1).
Comparison between Patients with and 
without BIM Deletion Polymorphism
There were no significant differences in the clinical 
characteristics, RR, DCR, or incidence of adverse events 
between patients with (n = 13) and without (n = 57) BIM dele-
tion polymorphism (Tables 2 and 3).
Survival and Indicators of Shorter PFS
We estimated PFS and OS in patients with and without 
BIM deletion polymorphism. The patients with BIM deletion 
polymorphism had significantly shorter PFS than did those 
without BIM deletion polymorphism (median, 227 versus 
533 days; p < 0.001; Fig. 1). There was no significant differ-
ence in OS (median, 1176 versus 1363 days; p = 0.27; Fig. 2). 
Multivariate Cox regression analysis showed that BIM dele-
tion polymorphism was the strongest independent indicator of 
shorter PFS (hazard ratio [HR], 3.99; 95% confidence interval 
[CI], 1.864–8.547; p < 0.001; Table 4).
DISCUSSION
BIM deletion polymorphism is a germline alteration 
that affects EGFR-TKI–related apoptosis.17,18 In a study that 
screened 2597 healthy individuals, BIM deletion polymorphism 
was present in 12.3% of East Asians but absent in Africans and 
Europeans.22 In the present study, BIM deletion polymorphism 
was present in 13 of 70 Japanese patients (18.6%) with EGFR 
mutation-positive NSCLC and in six of 30 healthy Japanese 
volunteers (20%), a statistically insignificant difference. The 
TABLE 2.  Patient Characteristics (n = 70)
Patients with  
BIM Deletion (n = 13)
Patients without  
BIM Deletion (n = 57) p
Age 63.8 ± 6.7 65.4 ± 14.1 0.64
Sex male/female 4/9 15/42 0.74
PS 0/1/2 7/3/3 31/21/5 0.29
Pathological type
  Ad/Sq 13/0 50/7 0.18
Clinical stage
  IV/Rec 7/6 27/30 0.67
Smoking history
  Current/former/never 1/3/9 2/14/41 0.79
  Pack-years 11.1 ± 17.5 10.5 ± 24.5 0.90
EGFR mutation
  19Del/L858R/Other 6/7/0 27/28/2 0.78
First EGFR-TKI
  Gefitinib/erlotinib 13/0 52/5 0.26
Cytotoxic chemotherapy
  0/1/2/3/≥4 regimen(s) 4/1/2/3/3 14/16/6/8/13 0.60
  Mean ± SD 2 ± 1.63 2.1 ± 1.97 0.17
Chemotherapy after TKI (+/−)
  Platinum doublet 2/11 10/47 0.82
  Single agent 7/6 21/36 0.25
  TKI rechallenge 2/11 15/42 0.40
Site of metastasis (+/−)
  Brain 6/7 22/35 0.62
  Bone 7/6 17/40 0.09
  Liver 2/11 2/55 0.09
  Pulmonary 6/7 17/40 0.26
  Lymph nodes 4/9 10/47 0.28
No. of metastases (+/−)
  Organs ≥ 2 7/6 30/27 0.93
  Organs ≥ 3 2/11 7/50 0.76
PS, performance status; EGFR, epidermal growth factor receptor; 19Del, exon 19 
deletion; L858R, exon 21 L858R; EGFR-TKI, epidermal growth factor receptor tyrosine 
kinase inhibitor; Ad, adenocarcinoma; Sq, squamous cell carcinoma; Rec, recurrence 
after surgical resection.
TABLE 3.  Comparison of Clinical Response and Adverse 
Events after EGFR-TKI Therapy
Patients with  
BIM Deletion (n = 13)
Patients without  
BIM Deletion (n = 57) p
Clinical response (%)
  RR 61.5 64.9 0.81
  DCR 100 91.2 0.26
All adverse events (%)
  Rash 61.5 47.3 0.36
  Diarrhea 38.5 22.8 0.24
  AST/ALT 0 8.8 0.27
  Appetite loss 15.3 14.0 0.90
  Pneumonitis 0 14.0 0.15
CTC grade 3–5 (%)
  Rash 7.7 3.5 0.49
  Diarrhea 0 5.3 0.39
  AST/ALT 0 3.5 0.49
  Appetite loss 0 1.8 0.63
  Pneumonitis 0 7.0 0.32
RR, response rate; DCR, disease control rate; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; CTC, National Cancer Institute Common Terminology 
Criteria.
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overall frequency of BIM deletion polymorphism in our study 
(19%, n = 100) was higher than that noted in a previous report.22
Tagawa et al.23 reported homozygous BIM deletions in 
patients with mantle-cell lymphoma, and homozygous BIM 
deletion was found in 0.5% of East Asians.24 Among the pres-
ent 70 Japanese patients with NSCLC, one (1.4%) had homo-
zygous deletion and 12 had heterozygous deletion. Future 
studies should investigate the characteristics of patients with 
homozygous BIM deletion polymorphism to determine if this 
genotype results in worse clinical outcomes when compared 
with heterozygous BIM deletion.
There were no significant differences between clini-
cal characteristics, response to EGFR-TKI, or incidences of 
adverse events due to EGFR-TKI among patients with and 
without BIM deletion polymorphism. Thus, it is difficult to 
distinguish between patients with and without BIM deletion 
polymorphism on the basis of clinical characteristics alone. 
No patient with BIM deletion developed EGFR-TKI–related 
pneumonitis. BIM knockdown was reported to prevent 
FOXO3 (i.e., FKHRL1, a member of the forkhead transcrip-
tion factor subfamily)-mediated overproduction of reactive 
oxygen species and apoptosis.25 BIM deletion polymorphism 
might affect EGFR-TKI–related lung injury by preventing 
overproduction of reactive oxygen species. Further studies are 
needed to clarify the relationship between EGFR-TKI–related 
pneumonitis and BIM.
BIM deletion polymorphism, a germline alteration, is 
thought to be associated with intrinsic resistance to  EGFR-TKI 
and would likely result in primary resistance and no response 
to treatment. However, the present clinical outcomes were 
probably due to acquired resistance: when compared with 
patients without BIM polymorphism, those with BIM dele-
tion polymorphism had similar RRs and DCRs but shorter 
PFS. The reasons for these findings remain to be investigated. 
It has been hypothesized that EGFR-TKI–induced apoptosis 
does not completely depend on the BIM pathway and that 
tumor response to EGFR-TKI in patients with BIM deletion 
might depend on other proapoptotic regulators, which could 
have less-prolonged clinical activity than those of the BIM 
pathway. A second hypothesis is that BIM deletion polymor-
phism itself results in relative resistance to EGFR-TKI. Kuroda 
et al.26 showed that cancer cells were sensitive to small changes 
in BIM protein concentrations and that BIM protein concen-
tration exerted a dose-dependent effect on apoptosis and the 
degree of TKI resistance.26 In a report by Faber et al.,21 PFS was 
shorter (4.7 versus 13.7 mo, p = 0.007) among patients with 
low BIM RNA expression, which appeared to correlate with 
high BIM protein expression on immunohistochemistry. The 
RR after EGFR-TKI was worse among patients with low BIM 
RNA expression (44%) than among those with high BIM RNA 
expression (77%), although the difference was not statistically 
significant. Patients with BIM deletion polymorphism could 
be regarded as “carriers” that have varied BIM expression and 
clinical responses that are modulated by genetic or epigenetic 
interactions, a possibility that warrants further study. Although 
cells with BIM deletion polymorphism show decreased induc-
tion of exon-4–containing transcripts after TKI exposure,22 the 
response after prolonged TKI exposure should be investigated.
Ng et al.22 reported that patients with BIM deletion poly-
morphism had significantly shorter PFS than did patients with-
out BIM deletion polymorphism after EGFR-TKI treatment 
(6.6 versus 11.9 mo, p = 0.0027), but they did not report RR or 
OS. Our present study in a Japanese population yielded similar 
FIGURE 1.  Patients with BIM deletion polymorphism had 
significantly shorter progression-free survival than did those 
without BIM deletion polymorphism (median, 227 versus 533 
days; p < 0.001).
FIGURE 2.  There was no significant difference in overall 
survival between patients with and without BIM deletion 
polymorphism (median, 1176 versus 1363 days; p = 0.27).
TABLE 4.  Indicators of Shorter PFS after EGFR-TKI  
Treatment
Parameter HR 95% CI p
Univariate Cox regression analysis
  Sex
  (male vs. female)
1.50 1.022–3.413 0.04
  Bone metastasis 
(yes vs. no)
2.11 1.187–3.755 0.007
  Smoking history 
(pack-years)
1.012 1.002–1.022 0.017
  BIM deletion 4.03 1.944–8.340 <0.001
Multivariate Cox regression analysis
  BIM deletion 3.99 1.864–8.547 <0.001
HR, hazard ratio; CI, confidence interval.
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results: BIM deletion polymorphism was an independent indi-
cator of shorter PFS. However, there was no significant dif-
ference in OS among patients with and without BIM deletion 
polymorphism. Multivariate Cox regression analysis showed 
that indicators of shorter OS were EGFR-TKI–related pneumo-
nitis (HR, 3.52; 95% CI, 1.190–3.860; p = 0.023), brain metas-
tasis (HR, 2.14; 95% CI, 1.099–4.165; p = 0.025), and smoking 
history (HR, 1.001; 95% CI, 1.000–1.001; p = 0.026). EGFR-
TKI–related pneumonitis developed only in patients without 
BIM deletion polymorphism (n = 8, 14%) but has a detrimental 
effect on chemotherapy given after pneumonitis. Thus, EGFR-
TKI–related pneumonitis might have reduced OS among the 
present patients without BIM deletion, which possibly explains 
the lack of a significant difference in OS between patients with 
and without BIM deletion polymorphism in the present study.
BH3-mimetic drugs22 and histone deacetylase inhibi-
tors24 may be able to surmount BIM-associated resistance to 
EGFR-TKI. Our findings suggest that although there was no 
significant difference in RR or OS among patients with and 
without BIM deletion polymorphism, the addition of these 
drugs might prolong PFS. However, this study was a retro-
spective study at a single center. A prospective multicenter 
study should be conducted to investigate the clinical signifi-
cance of BIM deletion polymorphism on EGFR-TKI therapy. 
In addition, EGFR-TKI–related pneumonitis should be con-
sidered in any randomized prospective study of the clinical 
benefit of BH3-mimetic drugs or histone deacetylase inhibi-
tors for patients with BIM deletion polymorphism.
In conclusion, BIM deletion polymorphism, a germ-
line alteration, was successfully detected by PCR analysis 
of samples of peripheral blood and FFPE slides of surgical 
specimens, thus providing a minimally invasive and conve-
nient detection method. BIM deletion polymorphism was the 
strongest indicator of shorter PFS among patients with EGFR 
mutation-positive NSCLC treated with EGFR-TKI. Our 
results indicate that new treatment strategies should be estab-
lished for patients with BIM deletion polymorphism.
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